Genmab

Genmab/AbbVie’s phase‑3 EPCORE DLBCL‑1 study shows epcoritamab improves PFS and ORR, yet falls short of US OS approval—implications for patients, payers, and Genmab’s future strategy.

Genmab and AbbVie reveal that the U.S. phase‑3 EPCORE DLBCL‑1 trial of epcoritamab failed to improve overall survival in relapsed/refractory DLBCL, raising regulatory questions.

Genmab and Merus launch bispecific INCA33890, targeting TGFβR2 and PD‑1 to turn “cold” MSS colorectal cancers “hot,” promising a new immunotherapy option.

Genmab’s Phase 3 EPCORE DLBCL‑4 trial shows epcoritamab + lenalidomide cuts progression risk by ~60 % in relapsed/refractory DLBCL, with a manageable safety profile and potential for broader use.

Genmab’s modest share dip reflects a market‑wide pullback, not a firm‑specific slump. With a strong antibody pipeline, a Novartis partnership, and U.S. regulatory tailwinds, the Danish biopharma may still be poised for long‑term upside despite compe…

Genmab’s focus on antibody‑based therapies, especially epcoritamab’s early success, offers hospitals a promising yet complex option for improving DLBCL outcomes while navigating reimbursement and cost‑efficiency challenges.

Genmab’s epcoritamab shows 78‑92% response rates in elderly DLBCL patients, offering a safe, cost‑effective outpatient alternative to anthracycline or CAR‑T therapies, with strong market and reimbursement potential.

Genmab’s Q1 results show growth, but expanding the petosemtamab trial risks investor confidence; analysts stay bullish, citing pipeline strength and M&A prospects.

BNP Paribas upgrades Genmab to “outperform,” citing a strong ADC pipeline, high margins and VBR potential amid a growing oncology market.

Genmab’s 2025 AGM confirms strong antibody‑therapy growth and a $1.25 bn revenue lift, while outlining a 2026 strategy to navigate patent cliffs, value‑based pricing and potential M&A.